Functional analysis of a breast cancer-associated mutation in the intracellular domain of the metalloprotease ADAM12.

A recently identified breast cancer-associated mutation in the metalloprotease ADAM12 alters a potential dileucine trafficking signal, which could affect protein processing and cellular localization. ADAM12 belongs to the group of A Disintegrin And Metalloproteases (ADAMs), which are typically membr...

Full description

Bibliographic Details
Main Authors: Dorte Stautz, Ulla M Wewer, Marie Kveiborg
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3360752?pdf=render
_version_ 1819100736032604160
author Dorte Stautz
Ulla M Wewer
Marie Kveiborg
author_facet Dorte Stautz
Ulla M Wewer
Marie Kveiborg
author_sort Dorte Stautz
collection DOAJ
description A recently identified breast cancer-associated mutation in the metalloprotease ADAM12 alters a potential dileucine trafficking signal, which could affect protein processing and cellular localization. ADAM12 belongs to the group of A Disintegrin And Metalloproteases (ADAMs), which are typically membrane-associated proteins involved in ectodomain shedding, cell-adhesion, and signaling. ADAM12 as well as several members of the ADAM family are over-expressed in various cancers, correlating with disease stage. Three breast cancer-associated somatic mutations were previously identified in ADAM12, and two of these, one in the metalloprotease domain and another in the disintegrin domain, were investigated and found to result in protein misfolding, retention in the secretory pathway, and failure of zymogen maturation. The third mutation, p.L792F in the ADAM12 cytoplasmic tail, was not investigated, but is potentially significant given its location within a di-leucine motif, which is recognized as a potential cellular trafficking signal. The present study was motivated both by the potential relevance of this documented mutation to cancer, as well as for determining the role of the di-leucine motif in ADAM12 trafficking. Expression of ADAM12 p.L792F in mammalian cells demonstrated quantitatively similar expression levels and zymogen maturation as wild-type (WT) ADAM12, as well as comparable cellular localizations. A cell surface biotinylation assay demonstrated that cell surface levels of ADAM12 WT and ADAM12 p.L792F were similar and that internalization of the mutant occurred at the same rate and extent as for ADAM12 WT. Moreover, functional analysis revealed no differences in cell proliferation or ectodomain shedding of epidermal growth factor (EGF), a known ADAM12 substrate between WT and mutant ADAM12. These data suggest that the ADAM12 p.L792F mutation is unlikely to be a driver (cancer causing)-mutation in breast cancer.
first_indexed 2024-12-22T01:07:30Z
format Article
id doaj.art-680f0c25b78549399968adb490d5e7e8
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-22T01:07:30Z
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-680f0c25b78549399968adb490d5e7e82022-12-21T18:44:03ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0175e3762810.1371/journal.pone.0037628Functional analysis of a breast cancer-associated mutation in the intracellular domain of the metalloprotease ADAM12.Dorte StautzUlla M WewerMarie KveiborgA recently identified breast cancer-associated mutation in the metalloprotease ADAM12 alters a potential dileucine trafficking signal, which could affect protein processing and cellular localization. ADAM12 belongs to the group of A Disintegrin And Metalloproteases (ADAMs), which are typically membrane-associated proteins involved in ectodomain shedding, cell-adhesion, and signaling. ADAM12 as well as several members of the ADAM family are over-expressed in various cancers, correlating with disease stage. Three breast cancer-associated somatic mutations were previously identified in ADAM12, and two of these, one in the metalloprotease domain and another in the disintegrin domain, were investigated and found to result in protein misfolding, retention in the secretory pathway, and failure of zymogen maturation. The third mutation, p.L792F in the ADAM12 cytoplasmic tail, was not investigated, but is potentially significant given its location within a di-leucine motif, which is recognized as a potential cellular trafficking signal. The present study was motivated both by the potential relevance of this documented mutation to cancer, as well as for determining the role of the di-leucine motif in ADAM12 trafficking. Expression of ADAM12 p.L792F in mammalian cells demonstrated quantitatively similar expression levels and zymogen maturation as wild-type (WT) ADAM12, as well as comparable cellular localizations. A cell surface biotinylation assay demonstrated that cell surface levels of ADAM12 WT and ADAM12 p.L792F were similar and that internalization of the mutant occurred at the same rate and extent as for ADAM12 WT. Moreover, functional analysis revealed no differences in cell proliferation or ectodomain shedding of epidermal growth factor (EGF), a known ADAM12 substrate between WT and mutant ADAM12. These data suggest that the ADAM12 p.L792F mutation is unlikely to be a driver (cancer causing)-mutation in breast cancer.http://europepmc.org/articles/PMC3360752?pdf=render
spellingShingle Dorte Stautz
Ulla M Wewer
Marie Kveiborg
Functional analysis of a breast cancer-associated mutation in the intracellular domain of the metalloprotease ADAM12.
PLoS ONE
title Functional analysis of a breast cancer-associated mutation in the intracellular domain of the metalloprotease ADAM12.
title_full Functional analysis of a breast cancer-associated mutation in the intracellular domain of the metalloprotease ADAM12.
title_fullStr Functional analysis of a breast cancer-associated mutation in the intracellular domain of the metalloprotease ADAM12.
title_full_unstemmed Functional analysis of a breast cancer-associated mutation in the intracellular domain of the metalloprotease ADAM12.
title_short Functional analysis of a breast cancer-associated mutation in the intracellular domain of the metalloprotease ADAM12.
title_sort functional analysis of a breast cancer associated mutation in the intracellular domain of the metalloprotease adam12
url http://europepmc.org/articles/PMC3360752?pdf=render
work_keys_str_mv AT dortestautz functionalanalysisofabreastcancerassociatedmutationintheintracellulardomainofthemetalloproteaseadam12
AT ullamwewer functionalanalysisofabreastcancerassociatedmutationintheintracellulardomainofthemetalloproteaseadam12
AT mariekveiborg functionalanalysisofabreastcancerassociatedmutationintheintracellulardomainofthemetalloproteaseadam12